GE HealthCare Technologies Inc. reported second quarter 2026 financial results on July 29, 2026. Total revenue increased 5.7% to $5.3 billion, driven by Pharmaceutical Diagnostics and Advanced Imaging Solutions, while Patient Care Solutions declined 13.3%. Diluted earnings per share rose 16.5% to $1.24, supported by a net income of $561 million and tariff refunds totaling $129 million. The company recorded record organic order growth of 11.1%, resulting in a book-to-bill ratio of 1.15 times and a backlog of $23.9 billion. GE HealthCare reaffirmed its full-year 2026 guidance, including adjusted EPS between $4.80 and $5.00. The company operates in the medical technology industry, designing and manufacturing diagnostic imaging systems, patient monitoring solutions, and pharmaceutical diagnostics.
